PCN50 COST-MINIMIZATION ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL OR PEMETREXED AS A SECOND-LINE TRETAMENT OF ADVANCED NON-SMALL LUNG CANCER (NSCLC) IN THE CONDITIONS OF THE CZECH REPUBLIC
Nov 1, 2008, 00:00 AM
10.1016/S1098-3015(10)66586-2
https://www.valueinhealthjournal.com/article/S1098-3015(10)66586-2/fulltext
Section Title :
Section Order :
421
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)66586-2&doi=10.1016/S1098-3015(10)66586-2